Treatment
Treatment B clinical trials
We’re tracking 246 recruiting studies that include Treatment B, each written for real people, not researchers, below.
Recruiting studies
- NCT07514169RecruitingPhase 2
New Combination Drug for Older Adults with B-Cell Lymphoma
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
ShanghaiAges 70 years+ - NCT05334823RecruitingPhase 2
CAR T-cell treatment for CD19-positive relapsed leukemia in children
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
Beijing, Beijing MunicipalityAges 3–21 - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06503211RecruitingPhase 1
UTAA09 cell therapy for lymphoma
This trial tests a new cell therapy called UTAA09 for people with certain types of lymphoma that have not been treated with CAR T-cells before. It aims to see if the treatment is safe and works against tumors that have CD19 or CD20 proteins.
Hefei, AnhuiAges 18–75 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06948981RecruitingPhase 1/Phase 2
GT719 Injection for Relapsed CD19+ B-cell Cancers
This trial tests a new injection called GT719 for adults with B-cell cancers that have come back or not responded to treatment. The cancer cells must have a marker called CD19. The study aims to see if the treatment is safe and works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07255963RecruitingPhase 2
Pirtobrutinib, Lisaftoclax, and Rituximab for relapsed DLBCL
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Suzhou, JiangsuAges 18 years+ - NCT05492799Enrolling by invitationPhase 4
Study of AX 250 for MPS IIIB in children
This Phase 4 trial studies how safe, tolerable, and helpful ICV AX 250 is for people with MPS IIIB. It is for participants who already finished a prior AX 250 study and meet specific health and eligibility checks.
Oakland, CaliforniaAges Any age - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT07371923RecruitingPhase 2
Zanubrutinib combination therapy for newly diagnosed high-risk DLBCL
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06785324Recruiting
Nutrition and exercise for adults with ALL in the hospital
This trial tests whether adding a structured diet and exercise program during your hospital stay for newly diagnosed ALL can help your recovery. You must have a specific type of ALL and be receiving a certain chemotherapy regimen.
Chicago, IllinoisAges 18–50 - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT05052528RecruitingPhase 1
CAR T cell therapy for relapsed or refractory large B-cell lymphoma
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
Sacramento, CaliforniaAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06530511RecruitingPhase 2
PRO trial for elderly, frail patients with a type of lymphoma
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Nantong, JiangsuAges 60 years+ - NCT06503276RecruitingPhase 2
Orelabrutinib and radiation for a type of eye lymphoma
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT05874206Recruiting
Branch stent graft for fixing aorta problems in the chest
This trial tests whether a “branch” stent graft can safely repair certain problems in the descending aorta (the big blood vessel in the chest). It may help by sealing the problem while keeping blood flow to an important branch vessel in the left upper chest area.
ZurichAges 18 years+ - NCT06274320Recruiting
Testing a urea cream before actinic keratosis treatment
This trial tests whether applying a 30% urea cream (Lipikar) before Tolak® treatment helps treat actinic keratoses (rough, scaly spots) on the scalp. It may make the skin more receptive to the treatment.
WuppertalAges 18 years+ - NCT06850285Recruiting
CD30 CAR-T for relapsed or refractory CD30+ lymphoma
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Taiyuan, ShangxiAges 15–80 - NCT07078500RecruitingPhase 2
Orelabrutinib plus Pola-R-CHP for untreated non-GCB DLBCL
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hangzhou, ZhejiangAges 18–80
Common questions
- Are there clinical trials studying Treatment B?
- Yes. Clin2 currently lists 246 recruiting studies that include Treatment B, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Treatment B trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Treatment B an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Treatment B or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.